BMC Urology

Table 3 The prognostic factors for CRPC patients reported in previous studies

From: Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

	Patient characteristics							Prognostic factor
	Number of patients	PSA at DTX median	Age median	% bone meta	% visceral meta	% PSA >50 % reduction	OS median	Age	PS	Hb (Anemia)	CRP	PSA	PSA DT	PSA >50 % reduction	Pain	Bone scan progression	ALP	Visceral meta	Duration from initial ADT
Armstrong et al.	656	110	69	91	23	45–48	17.8–19.2	×	×	○		×	×		○	○		○
Nakano et al.	78	19.7	70	54	5	23		×	×	×		×	○		○※1	○※1		○※1	×
Shiota et al.	97	81.3	70	83.5	15.5	44.3	20.8	×	×	×		×	×		×	×	○	○	○
Bamias et al.	94	84	71	87		54	16.2	×	×	×		○			○				×
Matsuyama et al.	279	35.2	71	60.5	7.9	57.5	26	×		×	○	○		○			○	×
Ito et al.	80						14.5	×	×	○	○	×			×		×	×
Nuhn et al.	238	91.2–112.9	68.3	90.3	16.5		14.4–18.3	×	×	○		○			×		×
Present study	79	43.2	72	51.9	5	69.6	22.5	○	×	○	○※2	○			×		×		×

Abbreviations: PSA prostate-specific antigen, DTX docetaxel, OS overall survival, PS performance status, Hb haemoglibin, CRP C-reactive protein, PSA DT prostate-specific antigen doubling time, ALP alkaline phosphatase, ADT androgen deprivation therapy
○: Significant
×: Not significant
※1: The Armstrong risk classification was independent prognostic factor
※2: CRP-to-Albumin　Ratio was independent prognostic factor

Back to article page

ISSN: 1471-2490

Contact us

General enquiries: journalsubmissions@springernature.com